2023
Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems
Garcia-Manero G, McCloskey J, Griffiths E, Zeidan A, Yee K, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Lee S, Chan W, Souza S, Sano Y, Keer H, Savona M. Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems. Blood 2023, 142: 4619. DOI: 10.1182/blood-2023-188258.Peer-Reviewed Original ResearchInternational Prognosis Scoring SystemLow-risk MDSHigh-risk MDSLeukemia-free survivalIPSS-R scoreOverall survivalMDS subjectsClinical outcomesPatient outcomesC-indexConcordance indexScoring systemMDS/CMMLMedian overall survivalDifferent risk stratification systemsHarrell's concordance indexMyelodysplastic syndrome patientsHigh-risk populationRisk stratification systemHigh-risk categoryHR categoriesCycle 2Different risk categoriesTreatment discontinuationClinical response
2022
Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents
Zeidan A, Tsai S, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents. Blood 2022, 140: 10847-10848. DOI: 10.1182/blood-2022-167360.Peer-Reviewed Original ResearchPoster: MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups
Alrawabdeh J, Alzu'bi M, Hamadneh Y, Odeh N, Alzyoud M, Awidi A, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A, Bawa'neh H. Poster: MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s154. DOI: 10.1016/s2152-2650(22)00945-4.Peer-Reviewed Original ResearchMDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups
Alrawabdeh J, Alzu'bi M, Hamadneh Y, Odeh N, Alzyoud M, Awidi A, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A, Bawa'neh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s321. DOI: 10.1016/s2152-2650(22)01428-8.Peer-Reviewed Original ResearchPlatelet-lymphocyte ratioNeutrophil-lymphocyte ratioEASIX scoreMyelodysplastic syndromeFisher's exact testMDS patientsExact testStress Index scoresMedian ageEndothelial activationPrognostic valueFemale ratioRisk groupsIndex scoreMDS/MPN patientsAvailable prognostic systemsMultivariable Cox regressionJordan University HospitalMyelodysplastic syndrome patientsReferral centerIndependent predictorsAML transformationLymphocyte ratioCox regressionUnfavorable prognosis
2020
The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents
Joshi N, Kale H, Corman S, Hill K, Wert T, Zeidan A. The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-139642.Peer-Reviewed Original ResearchNon-persistent groupHealthcare resource useDirect medical costsHigh-risk myelodysplastic syndrome (MDS) patientsHR-MDS patientsNon-persistent patientsMyelodysplastic syndrome patientsHMA treatmentCurrent equity holderMedical costsHR-MDSPersistent patientsSyndrome patientsPropensity score-based inverse probabilityContinuous Medicare enrollmentTotal PPPM costsEnd Results-MedicareStem cell transplantRetrospective cohort designHealthcare spendingLoss of responseSubstantial cost burdenHospice care useCurrent employmentER costs
2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
Zeidan AM, Al Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma Myeloma & Leukemia 2015, 15: 705-710. PMID: 26440749, DOI: 10.1016/j.clml.2015.08.083.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesFirst-line therapyErythropoiesis-stimulating agentsFailure of treatmentTreatment failureInternational Working Group 2006 criteriaResponse rateSecond-line therapyMyelodysplastic syndrome patientsHigh response rateChromosome 5q deletionAzacitidine useHematologic improvementLenalidomide treatmentOverall survivalAnemic patientsMyelodysplastic syndromeSyndrome patientsLarge cohortLenalidomideAzacitidinePatientsLeukemic progressionClinical databaseTherapyGenome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Review Of Hematology 2015, 8: 155-158. PMID: 25697572, DOI: 10.1586/17474086.2015.1016905.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeHigh-risk myelodysplastic syndromeMolecular mutationsRecurrent molecular mutationsReliable clinical predictorsIndependent prognostic valueMyelodysplastic syndrome patientsUrgent clinical needIdentification of biomarkersAgent therapyClinical predictorsPrognostic valuePrognostic subgroupsSyndrome patientsVariable coursePatientsClinical implicationsTET2 mutationsClinical needSyndromeTherapyRecurrent mutationsBiomarkersHMAsResearch priorities
2012
Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.
Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178. DOI: 10.1182/blood.v120.21.3178.3178.Peer-Reviewed Original ResearchIron chelation therapyCongestive heart failureStudy cohortCardiac conduction disordersMedicare Part DTransfusion thresholdPerformance statusRed blood cellsMyelodysplastic syndromeRenal diseaseConduction disordersChelation therapyObservation periodHistory of CHFPart DCox proportional hazards modelICD-9-CM codesErythropoiesis-stimulating agentsCoronary artery diseaseEntire study cohortMyelodysplastic syndrome patientsEnd of studyProportional hazards modelUtilization patternsMedicare enrollment files